Show simple item record

dc.contributor.authorNooij, Sam
dc.contributor.authorDucarmon, Quinten R
dc.contributor.authorLaros, Jeroen F J
dc.contributor.authorZwittink, Romy D
dc.contributor.authorNorman, Jason M
dc.contributor.authorSmits, Wiep Klaas
dc.contributor.authorVerspaget, Hein W
dc.contributor.authorKeller, Josbert J
dc.contributor.authorTerveer, Elisabeth M
dc.contributor.authorKuijper, Ed J
dc.date.accessioned2021-07-12T11:46:56Z
dc.date.available2021-07-12T11:46:56Z
dc.date.issued2021-06-11
dc.identifier.pmid34126062
dc.identifier.doi10.1053/j.gastro.2021.06.009
dc.identifier.urihttp://hdl.handle.net/10029/625067
dc.description.abstractPatients with multiple recurrent Clostridioides difficile infection (rCDI) have a disturbed gut microbiota that can be restored by fecal microbiota transplantation (FMT). Despite extensive screening, healthy feces donors may carry bacteria in their intestinal tract that could have long-term health effects, such as potentially procarcinogenic polyketide synthase-positive (pks+) Escherichia coli. Here, we aim to determine whether the pks abundance and persistence of pks+E coli is influenced by pks status of the donor feces.en_US
dc.language.isoenen_US
dc.rightsCopyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.
dc.subjectColibactinen_US
dc.subjectColorectal Canceren_US
dc.subjectGenotoxinen_US
dc.subjectMicrobiomeen_US
dc.titleFecal Microbiota Transplantation Influences Procarcinogenic Escherichia coli in Recipient Recurrent Clostridioides difficile Patients.en_US
dc.typeArticleen_US
dc.identifier.eissn1528-0012
dc.identifier.journalGastroenterology 2021; 161(4):1218-28en_US
dc.source.journaltitleGastroenterology
dc.source.countryUnited States


This item appears in the following Collection(s)

Show simple item record